{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T00:27:22Z","timestamp":1760747242167,"version":"build-2065373602"},"reference-count":89,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s40272-025-00721-6","type":"journal-article","created":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T06:22:24Z","timestamp":1759126944000},"page":"735-747","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["History and Current Status of Growth Hormone Treatment in Children"],"prefix":"10.1007","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-9398-8172","authenticated-orcid":false,"given":"Camila C.","family":"Luz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6831-8520","authenticated-orcid":false,"given":"Paulo F.","family":"Collett-Solberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,29]]},"reference":[{"key":"721_CR1","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1177\/014107689809100511","volume":"91","author":"A Enderle","year":"1998","unstructured":"Enderle A. Dwarfism and gigantism in historical picture postcards. J R Soc Med. 1998;91:273\u20138. https:\/\/doi.org\/10.1177\/014107689809100511.","journal-title":"J R Soc Med"},{"issue":"3","key":"721_CR2","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s11102-008-0138-y","volume":"12","author":"WW de Herder","year":"2009","unstructured":"de Herder WW. Acromegaly and gigantism in the medical literature. Case descriptions in the era before and the early years after the initial publication of Pierre Marie (1886). Pituitary. 2009;12(3):236\u201344. https:\/\/doi.org\/10.1007\/s11102-008-0138-y.","journal-title":"Pituitary"},{"key":"721_CR3","first-page":"297","volume":"6","author":"P Marie","year":"1886","unstructured":"Marie P. Sur deux cas d\u2019acrom\u00e9galie; hypertrophie singuli\u00e8re non cong\u00e9nitale des extr\u00e9mit\u00e9s sup\u00e9rieures, inf\u00e9rieures et c\u00e9phalique. Rev Med Liege. 1886;6:297\u2013333.","journal-title":"Rev Med Liege"},{"key":"721_CR4","first-page":"531","volume":"8","author":"JF Babinski","year":"1900","unstructured":"Babinski JF. Tumeur du corps pituitaire sans acrom\u00e9galie et avec arr\u00eat de d\u00e9veloppement des organes g\u00e9nitaux. Rev Neurol. 1900;8:531\u20133.","journal-title":"Rev Neurol"},{"key":"721_CR5","first-page":"833","volume":"15","author":"A Fr\u00f6hlich","year":"1901","unstructured":"Fr\u00f6hlich A. Ein fall von tumor der hypophysis cerebri ohne akromegalie. Wiener Klinische Rundschau. 1901;15:833\u20136.","journal-title":"Wiener Klinische Rundschau"},{"key":"721_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1017\/S1755146300190201","volume":"28","author":"D McKenzie","year":"1913","unstructured":"McKenzie D. The Pituitary Body and its Disorders: Clinical States produced by Disorders of the Hypophysis Cerebri. By Harvey Cushing, M.D., Associate Professor of Surgery, the Johns Hopkins University, &c. Pp. 341. 319 illustrations. Philadelphia and London: J. B. Lippincott company. Price 18s. net. J Laryngol Otol. 1913;28:382\u201390. https:\/\/doi.org\/10.1017\/S1755146300190201.","journal-title":"J Laryngol Otol"},{"issue":"99","key":"721_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1126\/science.99.2566.183","volume":"1944","author":"CH Li","year":"1979","unstructured":"Li CH, Evans HM. The isolation of pituitary growth hormone. Science. 1979;1944(99):183\u20134. https:\/\/doi.org\/10.1126\/science.99.2566.183.","journal-title":"Science"},{"key":"721_CR8","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1073\/pnas.92.4.959","volume":"92","author":"SC Souza","year":"1995","unstructured":"Souza SC, Frick GP, Wang X, Kopchick JJ, Lobo RB, Goodman HM. A single arginine residue determines species specificity of the human growth hormone receptor. ProcNatl Acad Sci. 1995;92:959\u201363. https:\/\/doi.org\/10.1073\/pnas.92.4.959.","journal-title":"ProcNatl Acad Sci"},{"issue":"Suppl 1","key":"721_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.17458\/per.vol16.2018.bbk.ghdiscoverystructure","volume":"16","author":"M Buchman","year":"2018","unstructured":"Buchman M, Bell S, Kopchick JJ. Growth hormone discovery and structure. Pediatr Endocrinol Rev. 2018;16(Suppl 1):2\u201310. https:\/\/doi.org\/10.17458\/per.vol16.2018.bbk.ghdiscoverystructure.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"125","key":"721_CR10","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1126\/science.125.3253.884","volume":"1957","author":"JC Beck","year":"1979","unstructured":"Beck JC, McGarry EE, Dyrenfurth I, Venning EH. Metabolic effects of human and monkey growth hormone in man. Science. 1979;1957(125):884\u20135. https:\/\/doi.org\/10.1126\/science.125.3253.884.","journal-title":"Science"},{"key":"721_CR11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/nrendo.2018.22","volume":"14","author":"MB Ranke","year":"2018","unstructured":"Ranke MB, Wit JM. Growth hormone \u2014 past, present and future. Nat Rev Endocrinol. 2018;14:285\u2013300. https:\/\/doi.org\/10.1038\/nrendo.2018.22.","journal-title":"Nat Rev Endocrinol"},{"issue":"5","key":"721_CR12","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1210\/jcem-55-5-1003","volume":"55","author":"L Russo","year":"1982","unstructured":"Russo L, Moore WV. A comparison of subcutaneous and intramuscular administration of human growth hormone in the therapy of growth hormone deficiency. J Clin Endocrinol Metab. 1982;55(5):1003\u20136. https:\/\/doi.org\/10.1210\/jcem-55-5-1003.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1530\/acta.0.1040148","volume":"104","author":"KW Kastrup","year":"1983","unstructured":"Kastrup KW, Christiansen JS, Andersen JK, \u00d8rskov H. Increased growth rate following transfer to daily sc administration from three weekly im injections of hGH in growth hormone deficient children. Acta Endocrinol (Copenh). 1983;104:148\u201352. https:\/\/doi.org\/10.1530\/acta.0.1040148.","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"3","key":"721_CR14","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1542\/peds.76.3.361","volume":"76","author":"DM Wilson","year":"1985","unstructured":"Wilson DM, Baker B, Hintz RL, Rosenfeld RG. Subcutaneous versus intramuscular growth hormone therapy: growth and acute somatomedin response. Pediatrics. 1985;76(3):361\u20134.","journal-title":"Pediatrics"},{"key":"721_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1111\/j.1651-2227.1987.tb17138.x","volume":"76","author":"K Albertsson-Wikland","year":"1987","unstructured":"Albertsson-Wikland K. The effect of human growth hormone injection frequency on linear growth rate. Acta Paediatr Scand. 1987;76:110\u20136. https:\/\/doi.org\/10.1111\/j.1651-2227.1987.tb17138.x.","journal-title":"Acta Paediatr Scand"},{"issue":"6","key":"721_CR16","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/adc.66.6.686","volume":"66","author":"PD Gluckman","year":"1991","unstructured":"Gluckman PD, Cutfield WS. Evaluation of a pen injector system for growth hormone treatment. Arch Dis Child. 1991;66(6):686\u20138. https:\/\/doi.org\/10.1136\/adc.66.6.686.","journal-title":"Arch Dis Child"},{"key":"721_CR17","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3201\/eid1806.120116","volume":"18","author":"P Brown","year":"2012","unstructured":"Brown P, Brandel J-P, Sato T, Nakamura Y, MacKenzie J, Will RG, et al. Iatrogenic Creutzfeldt-jakob disease, final assessment. Emerg Infect Dis. 2012;18:901\u20137. https:\/\/doi.org\/10.3201\/eid1806.120116.","journal-title":"Emerg Infect Dis"},{"key":"721_CR18","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/281544a0","volume":"281","author":"DV Goeddel","year":"1979","unstructured":"Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura DG, et al. Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 1979;281:544\u20138. https:\/\/doi.org\/10.1038\/281544a0.","journal-title":"Nature"},{"issue":"Suppl 1","key":"721_CR19","doi-asserted-by":"publisher","first-page":"17","DOI":"10.17458\/per.vol16.2018.p.sequenceproductionmetgh","volume":"16","author":"JS Parks","year":"2018","unstructured":"Parks JS. Gene sequence and production of recombinant MetGH\/hGH. Pediatr Endocrinol Rev. 2018;16(Suppl 1):17\u201327. https:\/\/doi.org\/10.17458\/per.vol16.2018.p.sequenceproductionmetgh.","journal-title":"Pediatr Endocrinol Rev"},{"key":"721_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1111\/apa.15948","volume":"111","author":"A Tidblad","year":"2022","unstructured":"Tidblad A. The history, physiology and treatment safety of growth hormone. Acta Paediatr. 2022;111:215\u201324. https:\/\/doi.org\/10.1111\/apa.15948.","journal-title":"Acta Paediatr"},{"key":"721_CR21","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.beem.2016.11.005","volume":"30","author":"E Richmond","year":"2016","unstructured":"Richmond E, Rogol AD. Treatment of growth hormone deficiency in children, adolescents and at the transitional age. Best Pract Res Clin Endocrinol Metab. 2016;30:749\u201355. https:\/\/doi.org\/10.1016\/j.beem.2016.11.005.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"721_CR22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1159\/000452150","volume":"86","author":"A Grimberg","year":"2016","unstructured":"Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, Quintos JB, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr. 2016;86:361\u201397. https:\/\/doi.org\/10.1159\/000452150.","journal-title":"Horm Res Paediatr"},{"key":"721_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000502231","volume":"92","author":"PF Collett-Solberg","year":"2019","unstructured":"Collett-Solberg PF, Ambler G, Backeljauw PF, Bidlingmaier M, Biller BMK, Boguszewski MCS, et al. Diagnosis, genetics, and therapy of short stature in children: a growth hormone research society international perspective. Horm Res Paediatr. 2019;92:1\u201314. https:\/\/doi.org\/10.1159\/000502231.","journal-title":"Horm Res Paediatr"},{"key":"721_CR24","doi-asserted-by":"publisher","first-page":"E372","DOI":"10.9778\/cmajo.20180020","volume":"6","author":"C Deal","year":"2018","unstructured":"Deal C, Kirsch S, Chanoine J-P, Lawrence S, Cummings E, Rosolowsky ET, et al. Growth hormone treatment of Canadian children: results from the GeNeSIS phase IV prospective observational study. CMAJ Open. 2018;6:E372\u201383. https:\/\/doi.org\/10.9778\/cmajo.20180020.","journal-title":"CMAJ Open"},{"key":"721_CR25","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1159\/000492397","volume":"90","author":"R Pf\u00e4ffle","year":"2018","unstructured":"Pf\u00e4ffle R, Land C, Sch\u00f6nau E, Holterhus P-M, Ross JL, Piras de Oliveira C, et al. Growth hormone treatment for short stature in the USA, Germany and France: 15 years of surveillance in the Genetics and Neuroendocrinology of Short-Stature International Study (GeNeSIS). Horm Res Paediatr. 2018;90:169\u201380. https:\/\/doi.org\/10.1159\/000492397.","journal-title":"Horm Res Paediatr"},{"key":"721_CR26","doi-asserted-by":"publisher","first-page":"3287","DOI":"10.1210\/clinem\/dgac517","volume":"107","author":"M Maghnie","year":"2022","unstructured":"Maghnie M, Ranke MB, Geffner ME, Vlachopapadopoulou E, Ib\u00e1\u00f1ez L, Carlsson M, et al. Safety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort. J Clin Endocrinol Metab. 2022;107:3287\u2013301. https:\/\/doi.org\/10.1210\/clinem\/dgac517.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR27","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41581-019-0161-4","volume":"15","author":"J Drube","year":"2019","unstructured":"Drube J, Wan M, Bonthuis M, W\u00fchl E, Bacchetta J, Santos F, et al. Clinical practice recommendations for growth hormone treatment in children with chronic kidney disease. Nat Rev Nephrol. 2019;15:577\u201389. https:\/\/doi.org\/10.1038\/s41581-019-0161-4.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"721_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003264.pub3","volume":"2012","author":"EM Hodson","year":"2012","unstructured":"Hodson EM, Willis NS, Craig JC. Growth hormone for children with chronic kidney disease. Cochrane Database Syst Rev. 2012;2012(2):CD003264. https:\/\/doi.org\/10.1002\/14651858.CD003264.pub3.","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"721_CR29","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1056\/NEJM200009283431304","volume":"343","author":"D Haffner","year":"2000","unstructured":"Haffner D, Schaefer F, Nissel R, W\u00fchl E, T\u00f6nshoff B, Mehls O, et al. Effect of growth hormone treatment on the adult height of children with chronic renal failure. N Engl J Med. 2000;343(13):923\u201330. https:\/\/doi.org\/10.1056\/NEJM200009283431304.","journal-title":"N Engl J Med"},{"key":"721_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1186\/s13023-022-02423-5","volume":"17","author":"E Fiot","year":"2022","unstructured":"Fiot E, Alauze B, Donadille B, Samara-Boustani D, Houang M, De Filippo G, et al. Turner syndrome: French National Diagnosis and Care Protocol (NDCP; National Diagnosis and Care Protocol). Orphanet J Rare Dis. 2022;17:261. https:\/\/doi.org\/10.1186\/s13023-022-02423-5.","journal-title":"Orphanet J Rare Dis"},{"key":"721_CR31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003887.pub2","author":"L Baxter","year":"2007","unstructured":"Baxter L, Bryant J, Cave CB, Milne R. Recombinant growth hormone for children and adolescents with Turner syndrome. Cochrane Database Syst Rev. 2007. https:\/\/doi.org\/10.1002\/14651858.CD003887.pub2.","journal-title":"Cochrane Database Syst Rev"},{"key":"721_CR32","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1210\/jcem.87.5.8477","volume":"87","author":"CA Quigley","year":"2002","unstructured":"Quigley CA, Crowe BJ, Anglin DG, Chipman JJ. Growth hormone and low dose estrogen in Turner syndrome: results of a United States multi-center trial to near-final height. J Clin Endocrinol Metab. 2002;87:2033\u201341. https:\/\/doi.org\/10.1210\/jcem.87.5.8477.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR33","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1210\/jc.2004-2187","volume":"90","author":"DK Stephure","year":"2005","unstructured":"Stephure DK, Canadian Growth Hormone Advisory Committee. Impact of growth hormone supplementation on adult height in Turner syndrome: results of the Canadian randomized controlled trial. J Clin Endocrinol Metab. 2005;90:3360\u20136. https:\/\/doi.org\/10.1210\/jc.2004-2187.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR34","doi-asserted-by":"publisher","first-page":"E1072","DOI":"10.1210\/jc.2012-3888","volume":"98","author":"CL Deal","year":"2013","unstructured":"Deal CL, Tony M, H\u00f6ybye C, Allen DB, Tauber M, Christiansen JS. Growth hormone research society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab. 2013;98:E1072\u201387. https:\/\/doi.org\/10.1210\/jc.2012-3888.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR35","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.jpeds.2004.08.002","volume":"145","author":"AL Carrel","year":"2004","unstructured":"Carrel AL, Moerchen V, Myers SE, Bekx MT, Whitman BY, Allen DB. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr. 2004;145:744\u20139. https:\/\/doi.org\/10.1016\/j.jpeds.2004.08.002.","journal-title":"J Pediatr"},{"issue":"13","key":"721_CR36","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1002\/ajmg.a.31824","volume":"143A","author":"MA Angulo","year":"2007","unstructured":"Angulo MA, Castro-Magana M, Lamerson M, Arguello R, Accacha S, Khan A. Final adult height in children with Prader-Willi syndrome with and without human growth hormone treatment. Am J Med Genet A. 2007;143A(13):1456\u201361. https:\/\/doi.org\/10.1002\/ajmg.a.31824.","journal-title":"Am J Med Genet A"},{"issue":"5","key":"721_CR37","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1210\/jc.2016-2962","volume":"102","author":"NE Bakker","year":"2017","unstructured":"Bakker NE, Lindberg A, Heissler J, Wollmann HA, Camacho-H\u00fcbner C, Hokken-Koelega AC, et al. Growth hormone treatment in children with Prader-Willi syndrome: three years of longitudinal data in prepubertal children and adult height data from the KIGS database. J Clin Endocrinol Metab. 2017;102(5):1702\u201311. https:\/\/doi.org\/10.1210\/jc.2016-2962.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/20420188241264343","volume":"15","author":"C L\u00e4mmer","year":"2024","unstructured":"L\u00e4mmer C, Backeljauw P, Tauber M, Kanumakala S, Loche S, Otfried Schwab K, et al. Growth hormone treatment in children with Prader-Willi syndrome: safety and effectiveness data from the PATRO Children study. Ther Adv Endocrinol Metab. 2024;15:20420188241264343. https:\/\/doi.org\/10.1177\/20420188241264343.","journal-title":"Ther Adv Endocrinol Metab"},{"key":"721_CR39","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1210\/jcem.87.4.8414","volume":"87","author":"AL Carrel","year":"2002","unstructured":"Carrel AL, Myers SE, Whitman BY, Allen DB. Benefits of long-term GH therapy in Prader-Willi syndrome: a 4-year study. J Clin Endocrinol Metab. 2002;87:1581\u20135. https:\/\/doi.org\/10.1210\/jcem.87.4.8414.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR40","doi-asserted-by":"publisher","first-page":"207","DOI":"10.2174\/1573396315666190716120925","volume":"15","author":"MG Butler","year":"2019","unstructured":"Butler MG, Miller JL, Forster JL. Prader-willi syndrome - clinical genetics, diagnosis and treatment approaches: an update. Curr Pediatr Rev. 2019;15:207\u201344. https:\/\/doi.org\/10.2174\/1573396315666190716120925.","journal-title":"Curr Pediatr Rev"},{"key":"721_CR41","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1210\/endrev\/bnad002","volume":"44","author":"ACS Hokken-Koelega","year":"2023","unstructured":"Hokken-Koelega ACS, van der Steen M, Boguszewski MCS, Cianfarani S, Dahlgren J, Horikawa R, et al. International consensus guideline on small for gestational age: etiology and management from infancy to early adulthood. Endocr Rev. 2023;44:539\u201365. https:\/\/doi.org\/10.1210\/endrev\/bnad002.","journal-title":"Endocr Rev"},{"key":"721_CR42","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1542\/peds.111.6.1253","volume":"111","author":"PA Lee","year":"2003","unstructured":"Lee PA, Chernausek SD, Hokken-Koelega ACS, Czernichow P. International small for gestational age advisory board consensus development conference statement: management of short children born small for gestational age, April 24\u2013October 1, 2001. Pediatrics. 2003;111:1253\u201361. https:\/\/doi.org\/10.1542\/peds.111.6.1253.","journal-title":"Pediatrics"},{"key":"721_CR43","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jped.2018.10.015","volume":"95","author":"AA Cardoso-Demartini","year":"2019","unstructured":"Cardoso-Demartini AA, Boguszewski MCS, Alves CAD. Postnatal management of growth failure in children born small for gestational age. J Pediatr (Rio J). 2019;95:23\u20139. https:\/\/doi.org\/10.1016\/j.jped.2018.10.015.","journal-title":"J Pediatr (Rio J)"},{"key":"721_CR44","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1111\/cen.12677","volume":"82","author":"JS Renes","year":"2015","unstructured":"Renes JS, Willemsen RH, Mulder JC, Bakker-van Waarde WM, Rotteveel J, Oostdijk W, et al. New insights into factors influencing adult height in short SGA children: results of a large multicentre growth hormone trial. Clin Endocrinol (Oxf). 2015;82:854\u201361. https:\/\/doi.org\/10.1111\/cen.12677.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"721_CR45","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1001\/jama.2014.3970","volume":"311","author":"LE Cohen","year":"2014","unstructured":"Cohen LE. Idiopathic short stature. JAMA. 2014;311:1787. https:\/\/doi.org\/10.1001\/jama.2014.3970.","journal-title":"JAMA"},{"key":"721_CR46","doi-asserted-by":"publisher","first-page":"c7157","DOI":"10.1136\/bmj.c7157","volume":"342","author":"A Deodati","year":"2011","unstructured":"Deodati A, Cianfarani S. Impact of growth hormone therapy on adult height of children with idiopathic short stature: systematic review. BMJ. 2011;342:c7157\u2013c7157. https:\/\/doi.org\/10.1136\/bmj.c7157.","journal-title":"BMJ"},{"key":"721_CR47","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1001\/archpedi.156.3.230","volume":"156","author":"BS Finkelstein","year":"2002","unstructured":"Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L. Effect of growth hormone therapy on height in children with idiopathic short stature. Arch Pediatr Adolesc Med. 2002;156:230. https:\/\/doi.org\/10.1001\/archpedi.156.3.230.","journal-title":"Arch Pediatr Adolesc Med"},{"key":"721_CR48","doi-asserted-by":"publisher","first-page":"4210","DOI":"10.1210\/jc.2008-0509","volume":"93","author":"P Cohen","year":"2008","unstructured":"Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, et al. Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology workshop. J Clin Endocrinol Metab. 2008;93:4210\u20137. https:\/\/doi.org\/10.1210\/jc.2008-0509.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR49","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1056\/NEJMra050100","volume":"353","author":"L Osterberg","year":"2005","unstructured":"Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487\u201397. https:\/\/doi.org\/10.1056\/NEJMra050100.","journal-title":"N Engl J Med"},{"key":"721_CR50","doi-asserted-by":"publisher","first-page":"3184","DOI":"10.1210\/clinem\/dgab529","volume":"106","author":"PS Thornton","year":"2021","unstructured":"Thornton PS, Maniatis AK, Aghajanova E, Chertok E, Vlachopapadopoulou E, Lin Z, et al. Weekly lonapegsomatropin in treatment\u2013na\u00efve children with growth hormone deficiency: the phase 3 heiGHt trial. J Clin Endocrinol Metab. 2021;106:3184\u201395. https:\/\/doi.org\/10.1210\/clinem\/dgab529.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR51","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1210\/clinem\/dgad183","volume":"108","author":"L S\u00e4vendahl","year":"2023","unstructured":"S\u00e4vendahl L, Battelino T, H\u00f8jby Rasmussen M, Brod M, R\u00f6hrich S, Saenger P, et al. Weekly somapacitan in GH deficiency: 4-year efficacy, safety, and treatment\/disease burden results from REAL 3. J Clin Endocrinol Metab. 2023;108:2569\u201378. https:\/\/doi.org\/10.1210\/clinem\/dgad183.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR52","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1080\/17425247.2017.1243526","volume":"14","author":"TR Rohrer","year":"2017","unstructured":"Rohrer TR, Horikawa R, Kappelgaard A-M. Growth hormone delivery devices: current features and potential for enhanced treatment adherence. Expert Opin Drug Deliv. 2017;14:1253\u201364. https:\/\/doi.org\/10.1080\/17425247.2017.1243526.","journal-title":"Expert Opin Drug Deliv"},{"key":"721_CR53","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1136\/adc.66.6.686","volume":"66","author":"PD Gluckman","year":"1991","unstructured":"Gluckman PD, Cutfield WS. Evaluation of a pen injector system for growth hormone treatment. Arch Dis Child. 1991;66:686\u20138. https:\/\/doi.org\/10.1136\/adc.66.6.686.","journal-title":"Arch Dis Child"},{"key":"721_CR54","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1111\/j.1651-2227.1988.tb10809.x","volume":"77","author":"K Albertsson-Wikland","year":"1988","unstructured":"Albertsson-Wikland K. Simplified growth hormone therapy \u2014 first clinical experience with the KabiPen. Acta Paediatr. 1988;77:103\u20136. https:\/\/doi.org\/10.1111\/j.1651-2227.1988.tb10809.x.","journal-title":"Acta Paediatr"},{"issue":"4","key":"721_CR55","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/s0022-3476(95)70372-1","volume":"126","author":"S Malozowski","year":"1995","unstructured":"Malozowski S, Stadel BV. Prepubertal gynecomastia during growth hormone therapy. J Pediatr. 1995;126(4):659\u201361. https:\/\/doi.org\/10.1016\/s0022-3476(95)70372-1.","journal-title":"J Pediatr"},{"issue":"1","key":"721_CR56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1210\/jc.2009-0178","volume":"95","author":"J Bell","year":"2010","unstructured":"Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167\u201377. https:\/\/doi.org\/10.1210\/jc.2009-0178.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9\u201310","key":"721_CR57","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1515\/jpem.2011.319","volume":"24","author":"R Noto","year":"2011","unstructured":"Noto R, Maneatis T, Frane J, Alexander K, Lippe B, Davis DA. Intracranial hypertension in pediatric patients treated with recombinant human growth hormone: data from 25 years of the Genentech National Cooperative Growth Study. J Pediatr Endocrinol Metab. 2011;24(9\u201310):627\u201331. https:\/\/doi.org\/10.1515\/jpem.2011.319.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"Suppl 5","key":"721_CR58","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000110474","volume":"68","author":"F Darendeliler","year":"2007","unstructured":"Darendeliler F, Karagiannis G, Wilton P. Headache, idiopathic intracranial hypertension and slipped capital femoral epiphysis during growth hormone treatment: a safety update from the KIGS database. Horm Res. 2007;68(Suppl 5):41\u20137. https:\/\/doi.org\/10.1159\/000110474.","journal-title":"Horm Res"},{"issue":"2","key":"721_CR59","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-15-0873","volume":"174","author":"DB Allen","year":"2016","unstructured":"Allen DB, Backeljauw P, Bidlingmaier M, Biller BM, Boguszewski M, Burman P, et al. GH safety workshop position paper: a critical appraisal of recombinant human GH therapy in children and adults. Eur J Endocrinol. 2016;174(2):P1-9. https:\/\/doi.org\/10.1530\/EJE-15-0873.","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"721_CR60","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1210\/jc.2016-2046","volume":"102","author":"AJ Swerdlow","year":"2017","unstructured":"Swerdlow AJ, Cooke R, Beckers D, Borgstr\u00f6m B, Butler G, Carel JC, et al. Cancer risks in patients treated with growth hormone in childhood: the SAGhE European cohort study. J Clin Endocrinol Metab. 2017;102(5):1661\u201372. https:\/\/doi.org\/10.1210\/jc.2016-2046.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"721_CR61","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2020.5199","volume":"175","author":"A Tidblad","year":"2021","unstructured":"Tidblad A, Bottai M, Kieler H, Albertsson-Wikland K, S\u00e4vendahl L. Association of childhood growth hormone treatment with long-term cardiovascular morbidity. JAMA Pediatr. 2021;175(2):e205199. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.5199.","journal-title":"JAMA Pediatr"},{"key":"721_CR62","doi-asserted-by":"publisher","first-page":"e2121","DOI":"10.1210\/clinem\/dgz149","volume":"105","author":"BS Miller","year":"2020","unstructured":"Miller BS, Velazquez E, Yuen KCJ. Long-acting growth hormone preparations \u2013 current status and future considerations. J Clin Endocrinol Metab. 2020;105:e2121\u201333. https:\/\/doi.org\/10.1210\/clinem\/dgz149.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR63","doi-asserted-by":"publisher","first-page":"E1008","DOI":"10.1152\/ajpendo.00513.2001","volume":"283","author":"CA Jaffe","year":"2002","unstructured":"Jaffe CA, Turgeon DK, Lown K, Demott-Friberg R, Watkins PB. Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans. Am J Physiol Endocrinol Metab. 2002;283:E1008\u201315. https:\/\/doi.org\/10.1152\/ajpendo.00513.2001.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"721_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2023.106805","volume":"193","author":"C Mameli","year":"2023","unstructured":"Mameli C, Orso M, Calcaterra V, Wasniewska MG, Aversa T, Granato S, et al. Efficacy, safety, quality of life, adherence and cost-effectiveness of long-acting growth hormone replacement therapy compared to daily growth hormone in children with growth hormone deficiency: a systematic review and meta-analysis. Pharmacol Res. 2023;193:106805. https:\/\/doi.org\/10.1016\/j.phrs.2023.106805.","journal-title":"Pharmacol Res"},{"issue":"6","key":"721_CR65","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1210\/jc.2010-2819","volume":"96","author":"BM Biller","year":"2011","unstructured":"Biller BM, Ji HJ, Ahn H, Savoy C, Siepl EC, Popovic V, et al. Effects of once-weekly sustained-release growth hormone: a double-blind, placebo-controlled study in adult growth hormone deficiency. J Clin Endocrinol Metab. 2011;96(6):1718\u201326. https:\/\/doi.org\/10.1210\/jc.2010-2819.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"721_CR66","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1210\/jc.2011-2234","volume":"97","author":"F P\u00e9ter","year":"2012","unstructured":"P\u00e9ter F, Bidlingmaier M, Savoy C, Ji HJ, Saenger PH. Three-year efficacy and safety of LB03002, a once-weekly sustained-release growth hormone (GH) preparation, in prepubertal children with GH deficiency (GHD). J Clin Endocrinol Metab. 2012;97(2):400\u20137. https:\/\/doi.org\/10.1210\/jc.2011-2234.","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"721_CR67","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1210\/jc.2006-0514","volume":"91","author":"M Bidlingmaier","year":"2006","unstructured":"Bidlingmaier M, Kim J, Savoy C, Kim MJ, Ebrecht N, de la Motte S, et al. Comparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency. J Clin Endocrinol Metab. 2006;91(8):2926\u201330. https:\/\/doi.org\/10.1210\/jc.2006-0514.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR68","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1530\/EJE-16-0905","volume":"177","author":"X Luo","year":"2017","unstructured":"Luo X, Hou L, Liang L, Dong G, Shen S, Zhao Z, et al. Long-acting PEGylated recombinant human growth hormone (Jintrolong) for children with growth hormone deficiency: phase II and phase III multicenter, randomized studies. Eur J Endocrinol. 2017;177:195\u2013205. https:\/\/doi.org\/10.1530\/EJE-16-0905.","journal-title":"Eur J Endocrinol"},{"key":"721_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2019\/1438723","volume":"2019","author":"Y Qiao","year":"2019","unstructured":"Qiao Y, Wang Z, Han J, Li G. Use of PEGylated recombinant human growth hormone in Chinese children with growth hormone deficiency: a 24-month follow-up study. Int J Endocrinol. 2019;2019:1\u20137.","journal-title":"Int J Endocrinol"},{"issue":"7","key":"721_CR70","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00431-025-06268-5","volume":"184","author":"W Wu","year":"2025","unstructured":"Wu W, Wei H, Du H, Liang L, Gong C, Zhong Y, et al. Five-year safety and growth response of long-acting PEGylated recombinant human growth hormone in children with growth hormone deficiency-data from CGLS database. Eur J Pediatr. 2025;184(7):434.","journal-title":"Eur J Pediatr"},{"key":"721_CR71","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1055\/a-1842-0724","volume":"54","author":"X Gao","year":"2022","unstructured":"Gao X, Chen J, Cao B, Dou X, Peng Y, Su C, et al. First clinical study on long-acting growth hormone therapy in children with Turner syndrome. Horm Metab Res. 2022;54:389\u201395. https:\/\/doi.org\/10.1055\/a-1842-0724.","journal-title":"Horm Metab Res"},{"key":"721_CR72","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1210\/clinem\/dgad039","volume":"108","author":"L Hou","year":"2023","unstructured":"Hou L, Huang K, Gong C, Luo F, Wei H, Liang L, et al. Long-term pegylated GH for children with GH deficiency: a large, prospective, real-world study. J Clin Endocrinol Metab. 2023;108:2078\u201386. https:\/\/doi.org\/10.1210\/clinem\/dgad039.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR73","doi-asserted-by":"publisher","first-page":"4531","DOI":"10.1007\/s00431-024-05719-9","volume":"183","author":"L Xie","year":"2024","unstructured":"Xie L, Li Y, Zhang J, Guo S, Chen Q, Ma H, et al. Effect of long-acting PEGylated growth hormone for catch-up growth in children with idiopathic short stature: a 2-year real-world retrospective cohort study. Eur J Pediatr. 2024;183:4531\u20139. https:\/\/doi.org\/10.1007\/s00431-024-05719-9.","journal-title":"Eur J Pediatr"},{"key":"721_CR74","doi-asserted-by":"publisher","first-page":"1254231","DOI":"10.3389\/fped.2023.1254231","volume":"11","author":"MS Grillo","year":"2023","unstructured":"Grillo MS, Frank J, Saenger P. Long acting growth hormone (LAGH), an update. Front Pediatr. 2023;11:1254231. https:\/\/doi.org\/10.3389\/fped.2023.1254231.","journal-title":"Front Pediatr"},{"key":"721_CR75","doi-asserted-by":"publisher","first-page":"R171","DOI":"10.1530\/EC-17-0203","volume":"6","author":"K Sprog\u00f8e","year":"2017","unstructured":"Sprog\u00f8e K, Mortensen E, Karpf DB, Leff JA. The rationale and design of TransCon growth hormone for the treatment of growth hormone deficiency. Endocr Connect. 2017;6:R171\u201381. https:\/\/doi.org\/10.1530\/EC-17-0203.","journal-title":"Endocr Connect"},{"key":"721_CR76","doi-asserted-by":"publisher","first-page":"e2680","DOI":"10.1210\/clinem\/dgac217","volume":"107","author":"AK Maniatis","year":"2022","unstructured":"Maniatis AK, Casella SJ, Nadgir UM, Hofman PL, Saenger P, Chertock ED, et al. Safety and efficacy of lonapegsomatropin in children with growth hormone deficiency: enlighten trial 2-year results. J Clin Endocrinol Metab. 2022;107:e2680\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgac217.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR77","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1159\/000530522","volume":"96","author":"EH Alkhatib","year":"2023","unstructured":"Alkhatib EH, Dauber A, Estrada DE, Majidi S. Weekly growth hormone (lonapegsomatropin) causes severe transient hyperglycemia in a child with obesity. Horm Res Paediatr. 2023;96:542\u20136. https:\/\/doi.org\/10.1159\/000530522.","journal-title":"Horm Res Paediatr"},{"issue":"10","key":"721_CR78","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1210\/clinem\/dgad183.]","volume":"108","author":"L S\u00e4vendahl","year":"2023","unstructured":"S\u00e4vendahl L, Battelino T, H\u00f8jby Rasmussen M, Brod M, R\u00f6hrich S, Saenger P, et al. Weekly somapacitan in GH deficiency: 4-year efficacy, safety, and treatment\/disease burden results from REAL 3. J Clin Endocrinol Metab. 2023;108(10):2569\u201378. https:\/\/doi.org\/10.1210\/clinem\/dgad183.].","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"721_CR79","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/cen.15025","volume":"100","author":"J Mori","year":"2024","unstructured":"Mori J, Ohata Y, Fujisawa Y, Sato Y, R\u00f6hrich S, Rasmussen MH, et al. Effective growth hormone replacement with once-weekly somapacitan in Japanese children with growth hormone deficiency: results from REAL4, a phase 3 clinical trial. Clin Endocrinol (Oxf). 2024;100(4):389\u201398. https:\/\/doi.org\/10.1111\/cen.15025.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"721_CR80","doi-asserted-by":"publisher","first-page":"3090","DOI":"10.1210\/clinem\/dgad394","volume":"108","author":"BS Miller","year":"2023","unstructured":"Miller BS, Blair JC, Rasmussen MH, Maniatis A, Mori J, B\u00f6ttcher V, et al. Effective GH replacement with somapacitan in children with GHD: REAL4 2-year results and after switch from daily GH. J Clin Endocrinol Metab. 2023;108:3090\u20139. https:\/\/doi.org\/10.1210\/clinem\/dgad394.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR81","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/ejendo\/lvac008","volume":"188","author":"A Juul","year":"2023","unstructured":"Juul A, Backeljauw P, H\u00f8jby M, Kawai M, Kildemoes RJ, Linglart A, et al. Somapacitan in children born small for gestational age: a multi-centre, open-label, controlled phase 2 study. Eur J Endocrinol. 2023;188:19\u201330. https:\/\/doi.org\/10.1093\/ejendo\/lvac008.","journal-title":"Eur J Endocrinol"},{"key":"721_CR82","doi-asserted-by":"publisher","first-page":"e2717","DOI":"10.1210\/clinem\/dgac220","volume":"107","author":"CL Deal","year":"2022","unstructured":"Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, et al. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107:e2717\u201328. https:\/\/doi.org\/10.1210\/clinem\/dgac220.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR83","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000470842","volume":"87","author":"DM Fisher","year":"2017","unstructured":"Fisher DM, Rosenfeld RG, Jaron-Mendelson M, Amitzi L, Koren R, Hart G. Pharmacokinetic and pharmacodynamic modeling of MOD-4023, a long-acting human growth hormone, in growth hormone deficiency children. Horm Res Paediatr. 2017;87:324\u201332. https:\/\/doi.org\/10.1159\/000470842.","journal-title":"Horm Res Paediatr"},{"key":"721_CR84","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1210\/jc.2016-3547","volume":"102","author":"N Zelinska","year":"2017","unstructured":"Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, et al. Long-acting C-terminal peptide\u2013modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab. 2017;102:1578\u201387. https:\/\/doi.org\/10.1210\/jc.2016-3547.","journal-title":"J Clin Endocrinol Metab"},{"key":"721_CR85","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1515\/jpem-2022-0359","volume":"36","author":"Z Zadik","year":"2023","unstructured":"Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, et al. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. J Pediatr Endocrinol Metab. 2023;36:261\u20139. https:\/\/doi.org\/10.1515\/jpem-2022-0359.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"10","key":"721_CR86","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvac117","volume":"6","author":"AK Maniatis","year":"2022","unstructured":"Maniatis AK, Carakushansky M, Galcheva S, Prakasam G, Fox LA, Dankovcikova A, et al. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc. 2022;6(10):bvac117. https:\/\/doi.org\/10.1210\/jendso\/bvac117.","journal-title":"J Endocr Soc"},{"key":"721_CR87","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40267-022-00955-1","volume":"38","author":"ES Kim","year":"2022","unstructured":"Kim ES, Al-Salama ZT. Somatrogon in paediatric growth hormone deficiency: a profile of its use in the EU. Drugs Ther Perspect. 2022;38:501\u20137. https:\/\/doi.org\/10.1007\/s40267-022-00955-1.","journal-title":"Drugs Ther Perspect"},{"key":"721_CR88","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1007\/s12325-024-02966-y","volume":"41","author":"L de Fries Jensen","year":"2024","unstructured":"de Fries Jensen L, Antavalis V, Odgaard-Jensen J, Rossi A, Pietropoli A, H\u00f8jby M. Efficacy and safety of somapacitan relative to somatrogon and lonapegsomatropin in pediatric growth hormone deficiency: systematic literature review and network meta-analysis. Adv Ther. 2024;41:4098\u2013124. https:\/\/doi.org\/10.1007\/s12325-024-02966-y.","journal-title":"Adv Ther"},{"key":"721_CR89","doi-asserted-by":"publisher","first-page":"8061","DOI":"10.1038\/s41598-024-58616-4","volume":"14","author":"J Zhu","year":"2024","unstructured":"Zhu J, Yuan K, Rana S, Jakki SL, Bhat AS, Liang L, et al. Long-acting growth hormone in the treatment of growth hormone deficiency in children: a systematic literature review and network meta-analysis. Sci Rep. 2024;14:8061. https:\/\/doi.org\/10.1038\/s41598-024-58616-4.","journal-title":"Sci Rep"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-025-00721-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-025-00721-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T15:29:11Z","timestamp":1760714951000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-025-00721-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,29]]},"references-count":89,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["721"],"URL":"https:\/\/doi.org\/10.1007\/s40272-025-00721-6","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"type":"print","value":"1174-5878"},{"type":"electronic","value":"1179-2019"}],"subject":[],"published":{"date-parts":[[2025,9,29]]},"assertion":[{"value":"4 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Camila Clemente Luz has no conflict of interest, Paulo Ferrez Collett-Solberg has received travel grants and lecture fees from Pfizer, Novo Nordisk, and BioMarin.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the current study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All authors have read and approve the final version of the manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}